Assessing cancer diagnosis in children with birth defects

May 29, 2020

Scientific studies suggest that children with birth defects are at increased risk of cancer. However, it has not been assessed whether the type of cancer, the age at which they are diagnosed or the extent of cancer spread at the time of diagnosis, is different for children with birth defects compared to children without birth defects.

In this study led by Baylor College of Medicine and Texas Children's Hospital, researchers compared about 13,000 children with cancer but no birth defects with nearly 1,600 children with cancer and one or more birth defects. The results were published in the journal Cancer.

"We investigated 28 different types of cancer by analyzing data from population-based registries in four U.S. states. For eight cancer types, we saw differences in the frequencies of those cancers when comparing children with birth defects and children without," said first author Dr. Jeremy Schraw, instructor of pediatric oncology and part of the Center for Epidemiology and Population Health at Baylor.

The group of children with birth defects in this study did not include those with syndromes caused by chromosomal or single-gene alterations, such as Down syndrome or neurofibromatosis, whose increased cancer risk has been previously studied.

The researchers found that acute lymphoblastic leukemia (ALL), the most common childhood cancer in the general pediatric population (24.5 percent), constituted a smaller proportion of diagnoses (12.4 percent) in children with birth defects. On the other hand, among children with birth defects, larger proportions of tumors were of embryonic origin, including neuroblastoma (12.5 percent vs. 8.2 percent) and hepatoblastoma (5 percent vs. 1.3 percent).

Regarding the age of diagnosis, the researchers found that the majority of these cancers were diagnosed 1 to 2 years earlier in children with birth defects than in children without.

Schraw and his colleagues also looked at the stage of cancer at diagnosis to address the possibility that cancers were diagnosed earlier in children with birth defects a result of the children getting more medical attention due to their condition, and during checkups cancer was found incidentally. If this were the case, the researchers expected that cancers in children with birth defects would more often be at an earlier stage at diagnosis than cancers in the general pediatric population.

"When we looked at the cancer stage at diagnosis, we found that, for the most part, there was no trend toward earlier stage at diagnosis in children with birth defects," said Schraw, who also is a member of Baylor's Dan L Duncan Comprehensive Cancer Center. "This suggests that increased medical surveillance alone does not explain the earlier age at diagnosis in children with birth defects."

"We hope that this research can inform future studies that will help us better understand cancer risk in children with birth defects," said corresponding author Dr. Philip Lupo, associate professor of pediatric hematology and oncology and member of the Dan L Duncan Comprehensive Cancer Center at Baylor. He also is the director of the Childhood Cancer Epidemiology and Prevention Program at Texas Children's Hospital. "However, it should be noted that while children with birth defects are more likely to develop cancer, their overall risk remains low."

"If we understand better the link between birth defects and cancer, we might be able to identify which of these children have a unique high risk of cancer and need surveillance," said co-author Dr. Sharon Plon, professor of pediatric oncology and of molecular and human genetics at Baylor. She also is a member of the Dan L Duncan Comprehensive Cancer Center.
-end-
Other contributors to this work include Tania Desrosiers, Wendy Nembhard, Peter Langlois, Robert Meyer, Mark Canfield, Sonja Rasmussen, Tiffany Chambers and Logan Spector. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, Texas Children's Hospital, University of North Carolina, University of Arkansas for Medical Sciences, Texas Department of State Health Services, North Carolina Division of Public Health, University of Florida College of Medicine and University of Minnesota.

This research was supported by Alex's Lemonade Stand Foundation (Epidemiology Award), the Cancer Prevention and Research Institute of Texas (RP140258, RP170071, RP160097) and the National Cancer Institute (3P30CA125123-0851).

Baylor College of Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.